Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. by Fesinmeyer, Megan Dann et al.
Impact of Population Trends in BMI on Prostate Cancer Incidence and 
Mortality in the US 
Megan Dann Fesinmeyer
1
 
Roman Gulati
1
 
Steve Zeliadt
2
 
Noel Weiss
3
 
Alan R. Kristal
1,3
 
Ruth Etzioni
1*
 
1
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, 
Washington 
2
Health Services Research and Development Center of Excellence, Department of Veterans 
Affairs Puget Sound Health Care System, Seattle, Washington 
3
Department of Epidemiology, School of Public Health and Community Medicine, University of 
Washington, Seattle, Washington 
 
Running title: Impact of obesity on prostate cancer trends 
Key words: Prostate cancer, obesity, incidence, mortality, simulation model 
                                                 
* Research supported by NCI/NIH U01-CA88160 and DOD/DAMD W81XWH-06-1-0296. Reprint requests to 
1100 Fairview Ave N, M2-B230, PO Box 19024, Seattle WA 98109-1024. Email: retzioni@fhcrc.org. 
ABSTRACT 
 
Concurrent with increasing prostate cancer incidence and declining prostate cancer mortality in 
the US, the prevalence of obesity has been rising steadily. Several studies have reported that 
obesity is associated with increased risk of high-grade prostate cancer and prostate cancer 
mortality, and it is thus likely that the rise in obesity has increased the burden of prostate cancer. 
In this study we assess the potential impact of rising obesity on prostate cancer incidence and 
mortality. We first estimate obesity-associated relative risks of low- and high-grade prostate 
cancer using data from the Prostate Cancer Prevention Trial. Then, using obesity prevalence data 
from the National Health and Nutrition Examination Survey and prostate cancer incidence data 
from the Surveillance, Epidemiology, and End Results program, we convert annual grade-
specific prostate cancer incidence rates into incidence rates conditional on weight category. Next, 
we combine the conditional incidence rates with the 1980 prevalence rates for each weight 
category to project annual grade-specific incidence under 1980 obesity levels. We use a 
simulation model based on observed survival and mortality data to translate the effects of obesity 
trends on prostate cancer incidence into effects on disease-specific mortality. The predicted rise 
in obesity prevalence since 1980 increased high-grade prostate cancer incidence by 15.5% and 
prostate cancer mortality by between 7.0% (under identical survival for obese and non-obese 
cases) and 23.0% (under different survival for obese and non-obese cases) in 2002. We conclude 
that increasing obesity prevalence since 1980 has partially obscured declines in prostate cancer 
mortality. 
INTRODUCTION 
 
Prostate cancer is the most common non-skin cancer in American men, with approximately 
219,000 new cases diagnosed in 2007 (1). From 1992 to 2004, prostate cancer death rates in the 
US dropped by a staggering 35% (2), most likely due to a combination of increased PSA 
screening and advances in prostate cancer treatment practices (3, 4). For example, data from 
Austria, the US, and the UK demonstrate that populations with high PSA screening rates have 
lower prostate cancer mortality rates than populations with low uptake of screening (5, 6). In 
addition to trends in treatment and screening practices, it is important to consider trends in 
population-level risk exposures such as obesity. 
 
Between 1980 and 2002, obesity (defined as body mass index (BMI)  ¸30 kg/m
2
) prevalence 
rates in men aged 40–74 more than doubled in the US, from 15% to 32% (7). In contrast, 
overweight (25 · BMI < 30) prevalence rates remained relatively constant at around 44% over 
this time period (7); see Figure 1. Obesity has been associated with a greater incidence of high-
grade prostate cancer (8-11), with poorer disease-specific survival (12) and clinical outcomes 
after cancer treatment (13), and with worse other-cause survival (14). 
 
The association between obesity and high-grade prostate cancer is biologically plausible because 
obesity is associated with marked alterations in the serum concentrations of numerous hormones 
such as estrogen, testosterone, insulin, insulin-like growth factor 1, all of which have been linked 
to prostate cancer, and leptin, which has been associated with high-grade prostate cancer. (15-
18). Obesity is also associated with increased levels of several biomarkers related to 
inflammation, including interleukin 6 and tumor necrosis factor-α (19). A number of publications 
have shown that chronic inflammation is associated with proliferative inflammatory lesions 
which may be precursors of prostate tumors (20-22). 
 
The association between obesity and low-grade prostate cancer is less clear. Although some 
studies have also linked obesity with a modestly reduced incidence of low-grade disease (11, 23), 
others have found no association (8, 24, 25). Several studies have found that obese men have 
very slightly decreased PSA levels (26-28) and enlarged prostates (29, 30). Thus, obese men 
with prostate cancer may be less likely to be referred to biopsy, and obese men receiving 
biopsies may be more likely to receive false negative results (31). However, there is much 
uncertainty about whether these potential diagnostic biases could substantially affect rates of 
low-grade disease. 
 
Given that obesity is associated with worse high-grade incidence and survival, and given that its 
protective effects for low-grade cancer are likely modest, the fact that mortality has declined 
despite increasing obesity suggests that even greater gains could have been seen had obesity rates 
remained constant over time. In this study we investigate the extent to which the increasing 
prevalence of obesity has increased prostate cancer incidence and mortality in the US. Our 
investigation uses data on grade-specific disease incidence, the annual prevalence of obesity in 
the US, and information from the Prostate Cancer Prevention Trial on the link between obesity 
and grade-specific incidence. With this information, we estimate the grade-specific prostate 
cancer incidence that would have been observed had the prevalence of obesity remained constant 
between 1980 and 2002 and compare projected and observed trends. We then use survival data to 
translate the difference between the grade-specific incidence curves under projected and 
observed trends into the impact of the observed rise in obesity on age-adjusted mortality. 
 
MATERIALS AND METHODS 
 
Our method to project grade-specific prostate cancer incidence had overweight and obese 
prevalence rates remained constant between 1980 and 2002 consists of two components: (a) 
calculating grade-specific incidence rates from 1980 to 2002 conditional on weight category 
(healthy, overweight, and obese) and (b) the conditional grade-specific incidence rates on weight 
category together with 1980 prevalence rates of each weight category to project overall, or 
unconditional, grade-specific incidence rates under 1980 obesity levels. Both components rely on 
weight trend data, patterns of prostate cancer incidence, and relative risks of low- and high-grade 
cancer associated with being overweight and obese. 
 
Trends in overweight and obese prevalence rates in the US 
 
Overweight and obese prevalence rates among American males aged 40–74 between 1980 and 
2002 were obtained from National Health and Nutrition Examination Survey (NHANES) public 
use data files (http://www.cdc.gov/nchs/nhanes.htm). NHANES has collected data on the health 
and nutritional status of adults and children in the US since the 1960s. The NHANES survey 
questions are administered to a nationally representative sample of individuals, and the survey 
results are extrapolated to produce estimates for the general population. NHANES did not collect 
data on men aged 75 or older until 1988; therefore our analysis is limited to men aged 40–74. 
NHANES defines healthy weight as BMI < 25, overweight as 25 · BMI < 30, and obese as BMI 
 ¸30. NHANES publishes age-specific data on population overweight and obese prevalence rates 
for 1976–1980, 1988–1994, and 1999–2002. We assumed that the NHANES results pertain to 
the midpoints of the survey years and used linear interpolation to impute prevalence rates for 
interim years. 
 
Prostate cancer incidence trends 
 
Prostate cancer incidence rates between 1980 and 2002 were obtained from the core nine 
population-based cancer registries contributing data to the Surveillance, Epidemiology, and End 
Results (SEER) program of the National Cancer Institute in this time period (32). We did not 
include available data from later years due to changes in SEER coding practices for prostate 
cancer grade beginning in 2003. Annual grade-specific incidence for men aged 40–74 was 
calculated as cases per 100,000 men using SEER*Stat software (http://seer.cancer.gov/seerstat/). 
Incidence rates were age-adjusted to the 2000 US standard population using seven 5-year age 
groups (40–44, …, 70–74). SEER grade categories well differentiated and moderately 
differentiated were grouped into a single category for low-grade cancer and poorly differentiated 
and undifferentiated were grouped into a single category for high-grade cancer. Cases with 
unknown grade were distributed into low- and high-grade categories in proportion to the relative 
number of known low- and high-grade cases in each year and age group. 
 
Relative risks of low- and high-grade prostate cancer for overweight and obese men 
 
Table 1 summarizes studies of the risk of high-grade prostate cancer associated with overweight 
and obese weight categories: there are five cohort studies (10, 11, 24, 25, 33), one case-control 
study (8), and one cohort study nested within a randomized controlled trial (23). These studies 
used a variety of definitions of high-grade prostate cancer and obesity, yet most reported at least 
some increased risk for high-grade prostate cancer associated with the highest category of BMI. 
To obtain risk estimates appropriate for weight categories consistent with NHANES definitions 
and grade categories consistent with SEER, we re-analyzed data from the Prostate Cancer 
Prevention Trial (PCPT). 
 
The PCPT was a randomized controlled trial conducted to investigate the efficacy of finasteride 
as a chemopreventive agent for prostate cancer. The trial enrolled 18,880 healthy men to receive 
either placebo or finasteride and provided annual prostate cancer screening for up to seven years 
of follow up. Our analysis considers the 911 participants diagnosed with prostate cancer 
following for-cause biopsy (i.e., biopsy triggered by suspicious PSA or DRE results) relative to 
the 9,347 participants who underwent end-of-study biopsy and therefore have known disease 
status. These definitions of case and control populations circumvent a potential problem in this 
dataset if associations of obesity with cases diagnosed without cause (i.e., detections among end-
of-study biopsies) differed from those diagnosed under standard clinical practice. A prior 
analysis of these data (23) demonstrated that men with BMI  ¸30 had a 78% increased risk of 
high-grade prostate cancer (Gleason grade 8–10) compared to men with BMI < 25. In contrast, 
BMI  ¸30 was associated with an 18% decreased risk of low-grade prostate cancer (Gleason 
score 2–7) compared to BMI < 25. 
 
In order to use risk estimates appropriate for NHANES weight categories, we re-analyzed the 
PCPT data considered in Gong et al. (23). First, we constructed NHANES weight categories w = 
1, 2, 3 for healthy weight (BMI < 25), overweight (25 · BMI < 30), and obese (BMI  ¸30). We 
then estimated grade-specific relative risks for categories 2 and 3 relative to 1 via Poisson 
regression modeling of individual-level observations, adjusting for age, race, family history of 
prostate cancer, diabetes status, and finasteride arm. The Poisson regressions yielded relative 
risks rgw for overweight low-grade (rL2), overweight high-grade (rH2), obese low-grade (rL3), 
and obese high-grade (rH3) prostate cancer incidence relative to healthy weight men. 
 
Grade-specific incidence trends conditional on weight categories 
 
We used the estimated relative risks to obtain annual grade-specific prostate cancer incidence 
conditional on weight category. By the law of total probability, the unconditional incidence rate 
for grade g and year y given age group a can be written: 
Ig(y j a) =
X
w
Ig(y j a; w)Py(w j a); (1) 
where Ig(y j a;w) denotes the incidence rate for grade g, year y, age group a, and weight 
category w and Py(w j a) represents the prevalence of weight category w in year y given age 
group a (with 
P
w Py(w j a) = 1). Using the relative risks rgw for g = L; H  and w = 2, 3 
estimated from the PCPT data we have: 
Ig(y j a;w) = rgw Ig(y j a; 1). 
We can now replace the terms for overweight and obese incidence in (1) with healthy weight 
incidence scaled by the risk of disease for individuals in these weight categories relative to 
healthy weight individuals. Consequently, for each grade g, year y, and age group a we have one 
equation in one unknown and can solve equation (1) for healthy weight incidence Ig(y j a; 1). 
With this solution, we immediately obtain incidence for overweight and obese individuals using 
the estimated relative risks. 
 
Projecting grade-specific incidence trends under 1980 obesity levels 
 
To project grade-specific incidence assuming that overweight and obese prevalence rates had 
remained constant at 1980 levels, we use the conditional grade-specific incidence rates computed 
above together with prevalence rates observed in 1980 as follows to approximate the expected 
incidence by grade, year, and age group: 
~Ig(y j a) =
X
w
Ig(y j a; w)P1980(w j a): 
Here the notation ~ designates unconditional grade-specific incidence under constant 1980 
overweight and obese prevalence rates. Comparing Ig(y j a) with ~Ig(y j a) allows us to estimate 
the impact of the observed rise in obesity in the US on prostate cancer incidence. To quantify the 
uncertainty in our estimates due to uncertainty in the estimated relative risks, we also estimate 
the impact of increasing obesity on high-grade prostate cancer incidence using endpoints of the 
95% confidence intervals (CIs) for the relative risks. 
 
As a by-product of this calculation we can estimate obesity distributions among prostate cancer 
cases by grade, year, and age group using Bayes theorem: 
Py(w j a; g) =
Ig(y j a; w)Py(w j a)P
!
Ig(y j a; !) Py(! j a)
; 
where Py(w j a; g) is the proportion of cases diagnosed in year y, age group a, and grade g who 
fall into weight category w. This ability to classify the low- and high-grade cases by obesity 
status at diagnosis is useful when we translate the impact of obesity on incidence into its impact 
on mortality. 
 
Impact on mortality 
 
To translate the impact on incidence into the impact on mortality, we use a microsimulation 
model of prostate cancer and other-cause death given grade-specific incidence patterns. The 
model first generates populations to match case counts by age group, year, and grade 
corresponding to observed and projected incidence rates Ig(y j a) and ~Ig(y j a). Each case is 
assigned a disease-specific and other-cause survival time from the date of diagnosis. Both 
survival times are allowed to depend on obesity status at diagnosis, which is assigned based on 
obesity distributions obtained as described above. 
 
We consider two prostate cancer survival hazard ratios for obese men: hpc = 1 (no effect of 
obesity on disease-specific survival) and hpc = 2:64 (obesity adversely affects disease-specific 
survival). These hazard ratios represent the instantaneous risk of death in obese versus non-obese 
prostate cancer cases. The latter hazard ratio was estimated by Gong et al. (34) for men aged 40–
64 but we assume for ages 65–74 as well. This estimate is remarkably similar to that reported by 
Ma et al. (35), who found a hazard ratio of 2.66 for obese versus non-obese prostate cancer cases 
in the Physicians Health Study. Analogous to our method for obtaining incidence rates by weight 
category using relative risks, we partition SEER cause-specific survival curves by age and year 
of diagnosis into weight-category-specific survival curves by noting that each corresponding 
hazard function is a weighted combination of the hazard functions for obese and non-obese with 
the weights given by the obesity distributions. For any hazard ratio of prostate cancer death, we 
can therefore solve for the survival among non-obese cases and use the hazard ratio to obtain 
survival among obese cases. The obese and non-obese cause-specific survival curves are derived 
under observed obesity trends in the population. The simulation model uses these curves to 
produce mortality projections corresponding to grade-specific incidence under both observed 
weight trends and under constant 1980 prevalence rates. 
 
Similarly, we consider two other-cause survival hazard ratios for obese men: hoc = 1 (no effect 
of obesity on disease-specific survival) and (hoc
1
; hoc
2
; hoc
3
) = (1:4; 1:2; 1:1) for age groups 40–54, 
55–64, and 65–74 (obesity adversely affects disease-specific survival). The latter set was 
estimated in (36). We assume that all-cause mortality hazard ratios are adequate approximations 
of other-cause mortality hazard ratios. 
 
Each case in the model is assigned a date of death given by the minimum of the dates of cause-
specific and other-cause death; cause of death is assigned accordingly. The model tabulates 
prostate cancer deaths by grade at diagnosis and age and year at death. The difference between 
the prostate cancer deaths under observed and constant 1980 weight trends each year is age-
adjusted and subtracted from observed mortality to project mortality trends had BMI prevalence 
rates remained at 1980 levels. Differences between the observed and projected mortality counts 
are inflated to the US population to estimate the number of excess deaths nationally due to 
observed increases in BMI in the population. To limit random variation due to the simulation 
model, results of 50 independent runs are averaged to produce the final results. 
 
To validate our model projections, we compare incidence-based mortality since 1980 (i.e., 
prostate cancer deaths among cases diagnosed after 1980 as a percentage of the population) 
observed in SEER and corresponding incidence-based mortality projected under observed 
obesity trends. This provides an opportunity to check that the overall number of deaths produced 
by the model reasonably approximates that observed in practice. 
 
RESULTS 
 
Table 2 reports cross-tabulation of Gleason grades and BMI categories for PCPT cases. The BMI 
distributions did not differ significantly between cases and controls. Table 2 also reports the 
estimated relative risks for overweight and obese men relative to healthy weight men by grade 
for all participants and for the placebo arm only. Considering data from all participants, we 
found that obesity (BMI ≥ 30) was associated with a non-significant decreased risk of low-grade 
prostate cancer. In contrast, obesity was associated with a significant 79% increased risk of high-
grade prostate cancer. Consistent with Gong et al. (23), we found that the higher risk of low- and 
high-grade prostate cancer for obese men was similar across study arms. They defined low-grade 
prostate cancer to consist of Gleason scores 6 and below and found a significant reduction in the 
risk of these tumors among obese men. We combined Gleason 7 with lower grade tumors for 
consistency with SEER data and to sidestep changes in grading practices over time that have 
resulted in a considerable shift from lower to higher grades within this group (37). 
 Figure 2 plots the observed incidence of low- and high-grade disease together with the projected 
incidence given 1980 overweight and obese prevalence rates using relative risks from our re-
analysis of PCPT data with 95% confidence limits. Results indicate that age-adjusted low-grade 
incidence would have been 280.8 (95% CI from 271.1 to 291.5) instead of the observed 277.1 
cases per 100,000 men, high-grade incidence would have been 50.1 (95% CI from 45.9 to 55.7) 
instead of the observed 57.8 cases per 100,000 men, and all-grade incidence would have been 
330.8 (95% CI from 317.1 to 347.2) instead of the observed 334.9 cases per 100,000 men in 
2002. In other words, the rise in obesity is estimated to have produced a 1.3% decrease in age-
adjusted low-grade incidence (95% CI from 4.9% decrease to 2.2% increase), a 15.5% increase 
in age-adjusted high-grade incidence (95% CI from 3.9% increase to 25.9% increase), and a 
0.7% increase in age-adjusted all-grade incidence (95% CI from 3.2% decrease to 4.4% increase) 
in 2002. See Table 3. 
 
Under equal risks of prostate cancer and other-cause death for obese men, model projections 
under observed obesity trends validate well, with small (less than 5%) mean relative errors 
across years for all age groups. The model projects increasing additional deaths attributable to 
rising obesity in all age groups, with 70% of these deaths among men aged 65–74. Totaling 
across years from 1980 to 2002, we estimate that increasing obesity could account for 5,687 of 
the observed 245,158 prostate cancer deaths in the US during this interval. After age-adjusting 
and converting to rates, we estimate that in 2002 the observed prostate cancer death rate was 
7.0% higher than would have been expected had obesity prevalence remained constant at 1980 
levels (95% CI from 0.4% lower to 11.5% higher). 
 Under higher risks of prostate cancer and other-cause death for obese men, model projections 
under observed obesity trends again validate well, with small (less than 8%) mean relative errors 
across years for all age groups. The model projects increasing additional deaths attributable to 
rising obesity in all age groups, again with 70% of these deaths among men aged 65–74. 
Summing over 1980 to 2002, we estimate that increasing obesity may be responsible for 19,370 
of the observed 245,158 prostate cancer deaths in the US in this interval. Age-adjusting and 
converting to rates, we estimate that in 2002 the observed prostate cancer death rate was 23.0% 
higher than would have been expected had obesity prevalence remained constant at 1980 levels 
(95% CI from 15.8% higher to 29.3% higher). Figure 3 illustrates the net impact on age-adjusted 
mortality rates under the two assumptions of risks of prostate cancer and other-cause death for 
obese men. 
 
DISCUSSION 
 
The consequences of the obesity epidemic in the US are far-reaching and, in the case of diseases 
like cardiac disease and diabetes, well studied. In recent years, evidence linking obesity with 
adverse outcomes in prostate cancer has accumulated, but the likely population impacts have not 
been quantified. We used NHANES data on overweight and obesity prevalence rates in 
conjunction with disease incidence, survival, and mortality data from SEER to quantify how 
prostate cancer trends have been affected by the rise in obesity in this country. We estimated that 
rising BMI levels since 1980 may have decreased low-grade incidence by 1.3% and increased 
high-grade incidence by 15.5%. In addition, we estimated that these trends may have increased 
prostate cancer deaths by between 7.0% (under obesity-independent disease-specific and other-
cause survival rates) and 23.0% (under different survival for obese and non-obese cases) in 2002. 
Our findings suggest that despite the dramatic declines in prostate cancer mortality observed 
since 1992, deaths from the disease might have declined even further had obesity prevalence 
rates not simultaneously increased. 
 
This study has several limitations. Although NHANES is an excellent source of population-
based obesity data, the NHANES survey was conducted intermittently between 1980 and 2002, 
and data were pooled over several years. We interpolated overweight and obesity levels for years 
with no survey data, assuming that overweight and obesity levels followed linear trends in the 
interim. In addition, our computations of grade-specific incidence given weight category in a 
given year and our estimates of the obesity-associated relative risks of low- and high-grade 
disease are based on current obesity status and do not take into account obesity history or 
duration. Although it is likely that the risk of prostate cancer at any given age depends on risk 
factors accumulated over several years, neither the NHANES data on obesity prevalence nor the 
PCPT data on risk of disease associated with obesity provide information on individual obesity 
histories. Our mortality simulation model allows obese and non-obese men to have different risks 
of prostate cancer death, but the magnitude of the increase in risk due to obesity is still uncertain. 
Some studies do not find a significant increase in risk, and, while a number of studies have found 
a positive association, only two (34, 35) provide estimates of the relative risk. Since the impact 
on mortality is highly dependent on how obesity affects the risk of prostate cancer death over and 
above its effect on high-grade incidence, it will be important to refine the estimate of the obesity-
associated risk of prostate cancer death provided as input to the model as more information 
becomes available. Thus, the uncertainty inherent in our mortality estimates is greater than what 
is reflected in confidence intervals, and may be reduced as more specific model inputs become 
available. 
 
In conclusion, current evidence indicates that trends in obesity have likely increased the 
incidence of high-grade prostate cancer over time, with a nontrivial effect on prostate cancer 
mortality through 2002. We conclude that in the absence of increasing prevalence of obesity, the 
decline in prostate cancer mortality in the US would have been noticeably more pronounced than 
was observed. This analysis underscores the complexity of the determinants of prostate cancer 
incidence and mortality trends and shows that it is likely that these trends depend on factors 
beyond screening and treatment. 
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Table 1. Previous studies of BMI and risk of high-grade prostate cancer 
Authors Population Study 
design 
BMI measurement Definition of high grade Risk measure (95% confidence interval) 
MacInnis et 
al. 2003 
16,336 men 
aged 27–75 
participating in 
MCCS 
Prospective 
cohort 
BMI < 25, 25 · BMI 
< 30, and BMI  ¸30; 
also used quartiles of 
fat mass 
Gleason score 8–10 or 
metastatic. 
RR = 2.2 (1.2–4.1)for BMI  ¸30 vs. BMI < 25 
RR = 1.1 (0.6–1.9) for 25 · BMI < 30 vs. BMI < 25 
adjusted for age, birthplace, education 
Dal Maso et 
al. 2004 
1294 cases and 
1451 controls 
aged 46–74 in 
Italy 
Hospital-
based case-
control 
Quartiles of BMI 
taken near diagnosis, 
recollection at age 
30, lifetime lowest. 
Gleason score 7–10 OR = 1.61 (1.13–2.28) for BMI  ¸28.41 vs. BMI < 24.22 
OR = 1.57 (1.11–2.22) for 26.18 · BMI < 28.41 vs. BMI < 24.22 
adjusted for age, location, education, family history, physical activity 
Gong et al. 
2006 
10,258 men in 
PCPT 
Randomized 
controlled 
trial 
BMI < 25, 25 · BMI 
< 27, 27 · BMI < 30, 
BMI  ¸30 measured 
1 year post 
randomization 
Gleason score 7–10, 
Gleason score 8–10 
OR = 1.29 (1.01–1.67) for BMI  ¸30 vs. BMI < 25, Gleason 7–10. 
OR = 1.78 (1.10–2.87) for BMI  ¸30 vs. BMI < 25, Gleason 8–10. 
adjusted for age, race, treatment, diabetes, family history 
Rodriguez et 
al. 2007 
69,991 men in 
CPS II 
Prospective 
cohort 
BMI < 25, 25 · BMI 
< 27.5, 27.5 · BMI < 
30, 30 · BMI < 35, 
BMI  ¸35 measured 
at enrollment 
Gleason score 8–10 and 
local-regional stage 
(“High grade”); distant 
stage or unknown stage 
but prostate cancer listed 
as primary cause on death 
certificate (“Metastatic”) 
“High grade” 
RR = 1.22 (0.96–1.55) for BMI  ¸30 vs. BMI < 25 
RR = 1.23 (1.00–1.53) for 27.5 · BMI < 30 vs. BMI < 25 
“Metastatic” 
RR = 1.54 (1.06–2.23) for BMI  ¸30 vs. BMI < 25 
RR = 1.14 (0.79–1.63) for 27.5 · BMI < 30 vs. BMI < 25 
adjusted for age, race, education, family history, total calorie intake, 
smoking, PSA history, diabetes, physical activity 
Giovannucci 
et al. 2007 
51,529 men in 
HPFS 
Prospective 
cohort 
BMI 21-22.9, 23-
24.9, 25-27.4, 27.5-
29.9, >30 measured 
at baseline 
Gleason score 7–10 RR = 1.07 (0.73–1.55) for BMI ≥ 30 vs. BMI < 21 
RR = 1.02 for BMI 27.5–29.9 vs. BMI < 21 
RR = 1.03 for BMI 25–27.4 vs. BMI < 21 
adjusted for age, time period, BMI at age 21, height, smoking, 
activity level, family history, diabetes, race, and dietary measures 
Littman et al. 
2007 
34,754 men in 
VITAL 
Prospective 
cohort 
BMI < 25, 25 · BMI 
< 30, BMI  ¸30 
measured at baseline 
Gleason score 8–10 or 
regional/distant stage 
HR = 1.3 (0.89–1.9) for 25 · BMI < 30 vs. BMI < 25 
HR = 1.1 (0.71–1.8) for BMI  ¸30 vs. BMI < 25 
adjusted for age, family history, race 
 
Pischon et al. 
2008 
148,372 men 
in EPIC 
Prospective 
cohort 
BMI < 25, 25 · BMI 
< 30, BMI  ¸30 
measured at baseline 
Gleason score 7–10, 
Gleason score 8–10 
HR = 1.09 (0.90–1.31) for 25 · BMI < 30 vs. BMI < 25 
HR = 1.08 (0.83–1.41) for BMI  ¸30 vs. BMI < 25 
Adjusted for smoking, education, alcohol consumption, height, and 
physical activity. 
Notes: MCCS is Melbourne Collaborative Cohort Study; PCPT is Prostate Cancer Prevention Trial; CPS is Cancer Prevention Study; HPFS is Health 
Professionals Follow-up Study; VITAL is Vitamins and Lifestyle Study; EPIC is European Prospective Investigation into Cancer and Nutrition.
 Table 2. Cross-tabulation of grade and BMI categories in PCPT data and estimated relative risks 
Cross-tabulation of grade and BMI categories in PCPT data 
  BMI < 25 25 ≤ BMI < 30 BMI ≥ 30  
  N (%) N (%) N (%)  
Total 
Cases          
 Low grade  213 (26.6) 420 (52.3) 169 (21.1)  802 
 High grade  23 (21.1) 49 (45.0) 37 (33.9)  109 
Controls  2,376 (25.4) 4,789 (51.2) 2,182 (23.3)  9,347 
Relative risks for overweight and obese men by arm and grade 
  BMI < 25 25 ≤ BMI < 30 BMI ≥ 30  
  Reference 
level 
RR (95% CI) 
p-value 
RR (95% CI) 
p-value 
 p-trend 
All participants       
 Low grade  1.00 1.01 (0.86–1.18) 
0.92 
0.93 (0.76–1.13) 
0.45 
 
0.47 
 High grade  1.00 1.13 (0.69–1.85) 
0.62 
2.00 (1.19–3.38) 
0.01 
 
0.01 
Placebo arm only       
 Low grade  1.00 0.96 (0.79–1.18) 
0.70 
0.89 (0.70–1.14) 
0.36 
 
0.37 
 High grade  1.00 1.29 (0.59–2.80) 
0.53 
1.75 (0.74–4.15) 
0.20 
 
0.20 
Notes: Low grade is defined as Gleason score 2–7 and high grade is defined as Gleason score 8–
10. Relative risks are adjusted for age, race, family history of prostate cancer, diabetes status, and 
PCPT study arm. 
Table 3. Projected impact of increasing obesity on grade-specific prostate cancer incidence and 
overall mortality among men aged 40–75 in 2002 
Impact on incidence per 100,000 men 
  Low grade  High grade  
Ages  Observed Projected %¢  Observed Projected %¢  
40–44  7.7 7.8 −1.0  0.9 0.8 12.0  
45–49  37.1 37.4 −0.9  5.5 5.0 11.1  
50–54  131.5 132.8 −0.9  23.7 21.3 11.1  
55–59  324.3 329.4 −1.5  58.3 50.0 16.6  
60–64  522.8 531.0 −1.5  101.6 87.1 16.6  
65–69  783.7 793.6 −1.3  173.2 149.8 15.6  
70–74  884.5 895.7 −1.3  212.2 183.5 15.6  
Adjusted  277.1 280.8 −1.3  57.8 50.1 15.5  
Impact on mortality per 100,000 men 
Projected  
Ages  Observed  
General %¢  BMI-specific %¢  
40–44  0.2  0.2 11.1  0.1 58.1  
45–49  0.8  0.7 7.5  0.6 28.2  
50–54  2.4  2.2 8.2  1.9 25.6  
55–59  7.3  6.7 9.1  5.3 37.1  
60–64  21.2  19.5 8.5  17.1 23.7  
65–69  47.0  43.4 8.4  38.5 22.2  
70–74  102.1  96.7 5.6  84.1 21.5  
Adjusted  16.9  15.8 7.0  13.7 23.0  
Notes: Projected incidence rates assume constant 1980 obesity prevalence rates and are based on 
relative risks re-estimated using PCPT data. Projected mortality rates use projected incidence and 
selected cause-specific and other-cause survival hazard ratios for obese men. General survival 
uses hazard ratios hpc = hoc = 1 for obese men while BMI-specific survival uses hpc = 2:64 and 
(hoc
1
; hoc
2
; hoc
3
) = (1:4; 1:2; 1:1) for obese men in age groups 40–54, 55–64, and 65–74. 
Figure 1. NHANES weight trends by age group. Prevalence proportions partition the population 
in each year into weight categories BMI < 25, 25 · BMI < 30, and BMI  ¸30. 
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Figure 2. Projected impact of increasing obesity on age-adjusted low-grade (left) and high-grade 
(right) prostate cancer incidence for men aged 40–75. Projections assume constant 1980 obesity 
prevalence rates and are based on relative risks re-estimated using PCPT data. 95% confidence 
limits are based on 95% confidence limits for estimated relative risks. 
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Figure 3. Projected impact of increasing obesity on prostate cancer mortality among men aged 
40–75. Projections are based on relative risks re-estimated using PCPT data and selected cause-
specific and other-cause survival hazard ratios. General survival uses hazard ratios hpc = hoc = 1 
for obese men while BMI-specific survival uses hpc = 2:64 and (hoc
1
; hoc
2
; hoc
3
) = (1:4; 1:2; 1:1) 
for obese men in age groups 40–54, 55–64, and 65–74. 
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